Paul Da Silva Jardine
About Paul Da Silva Jardine
Paul Da Silva Jardine: Venture Partner
Paul Da Silva Jardine serves as a Venture Partner. With extensive experience in the pharmaceutical industry, Jardine’s career spans influential roles in both scientific research and biotechnology entrepreneurship. He has contributed significantly to various high-profile drug discovery and development projects, exemplifying his dedication to advancing medical science.
Paul Da Silva Jardine's Career at Pfizer
Paul Da Silva Jardine spent 25 years at Pfizer Research, starting as the head of Cardiovascular and Metabolic Diseases (CVMD) Chemistry. Later, he advanced to the position of vice president of the CVMD Biology Research Unit. During his tenure, Jardine led teams that discovered and developed over 50 clinical candidates. Notably, two of these candidates were licensed by the FDA and EMA as human medicines, and two were approved as veterinary medicines.
Paul Da Silva Jardine's Role in Staten Biotechnology
Paul Da Silva Jardine founded and led Staten Biotechnology. At Staten, he spearheaded the development of the only known anti-ApoC3 antibody for the treatment of coronary heart disease. This innovation underscores his commitment to tackling significant health challenges through groundbreaking biotechnological solutions.
Paul Da Silva Jardine's Education and Research Background
Paul Da Silva Jardine received a BS in chemistry from the University of Texas at Austin. He furthered his education at Harvard University, where he earned a PhD and conducted postdoctoral research in synthetic organic chemistry in the labs of Nobel laureate chemist E.J. Corey. Jardine's robust educational background laid the foundation for his substantial contributions to pharmaceutical research and development.
Paul Da Silva Jardine's Contributions to Chinook Therapeutics
In addition to his other roles, Paul Da Silva Jardine created a program that was incorporated into ATP portfolio company Chinook Therapeutics. This highlights his ability to develop innovative pharmaceutical programs that align with the strategic goals of leading biotech firms.